坎地沙坦与缬沙坦联合氨氯地平对外周和中枢血压的安全性和有效性比较

IF 1.2 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS
S.M. Hanna , H.M. Rabea , M.E.A. Abdelrahim , H.B. Mahmoud
{"title":"坎地沙坦与缬沙坦联合氨氯地平对外周和中枢血压的安全性和有效性比较","authors":"S.M. Hanna ,&nbsp;H.M. Rabea ,&nbsp;M.E.A. Abdelrahim ,&nbsp;H.B. Mahmoud","doi":"10.1016/j.hipert.2023.11.004","DOIUrl":null,"url":null,"abstract":"<div><h3>Introduction</h3><p>“Amlodipine/valsartan” or “amlodipine/candesartan” combinations represent two effective antihypertensive agents with complementary mechanisms of action. Nevertheless, a study has yet to be done to evaluate the effect of amlodipine/candesartan on central blood pressure and compare it with amlodipine/valsartan combination. To see how “amlodipine plus candesartan combination” reduces peripheral and central blood pressure compared to the most studied combination, “amlodipine plus valsartan”.</p></div><div><h3>Material and methods</h3><p>Eighty-six patients were randomized in an open-label, prospective study by 1:1 ratio to two groups. Group I (<em>n</em> <!-->=<!--> <!-->42) received the amlodipine and valsartan combination, and group II (<em>n</em> <!-->=<!--> <!-->44) received the amlodipine and candesartan combination. Peripheral and central blood pressure (CBP) was measured at baseline, at 6 and 12 weeks of follow-up.</p></div><div><h3>Discussion</h3><p>Both treatment groups reduced peripheral systolic, diastolic, and mean blood pressure. There was no significant difference between and within both groups. The amlodipine/candesartan combination showed more reduction in peripheral systolic blood pressure (PSBP) after 12 weeks of treatment (<em>p</em> <!-->=<!--> <!-->&lt;0.001). Both groups decreased CBP without significant differences between groups. The amlodipine/candesartan combination showed additional efficacy in decreasing CSBP after 12 weeks (<em>p</em> <!-->=<!--> <!-->&lt;0.001). The two treatment groups did not exert significant efficacy in lowering heart rate (HR) and augmentation index% (AIx%).</p></div><div><h3>Conclusion</h3><p>To conclude, the amlodipine 10<!--> <!-->mg/candesartan 16<!--> <!-->mg combination was non-inferior to the amlodipine 10<!--> <!-->mg/valsartan 160<!--> <!-->mg combination in terms of reducing peripheral and CBP over time.</p></div>","PeriodicalId":39403,"journal":{"name":"Hipertension y Riesgo Vascular","volume":"41 1","pages":"Pages 17-25"},"PeriodicalIF":1.2000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Safety and efficacy of candesartan versus valsartan combined with amlodipine on peripheral and central blood pressure\",\"authors\":\"S.M. Hanna ,&nbsp;H.M. Rabea ,&nbsp;M.E.A. Abdelrahim ,&nbsp;H.B. Mahmoud\",\"doi\":\"10.1016/j.hipert.2023.11.004\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Introduction</h3><p>“Amlodipine/valsartan” or “amlodipine/candesartan” combinations represent two effective antihypertensive agents with complementary mechanisms of action. Nevertheless, a study has yet to be done to evaluate the effect of amlodipine/candesartan on central blood pressure and compare it with amlodipine/valsartan combination. To see how “amlodipine plus candesartan combination” reduces peripheral and central blood pressure compared to the most studied combination, “amlodipine plus valsartan”.</p></div><div><h3>Material and methods</h3><p>Eighty-six patients were randomized in an open-label, prospective study by 1:1 ratio to two groups. Group I (<em>n</em> <!-->=<!--> <!-->42) received the amlodipine and valsartan combination, and group II (<em>n</em> <!-->=<!--> <!-->44) received the amlodipine and candesartan combination. Peripheral and central blood pressure (CBP) was measured at baseline, at 6 and 12 weeks of follow-up.</p></div><div><h3>Discussion</h3><p>Both treatment groups reduced peripheral systolic, diastolic, and mean blood pressure. There was no significant difference between and within both groups. The amlodipine/candesartan combination showed more reduction in peripheral systolic blood pressure (PSBP) after 12 weeks of treatment (<em>p</em> <!-->=<!--> <!-->&lt;0.001). Both groups decreased CBP without significant differences between groups. The amlodipine/candesartan combination showed additional efficacy in decreasing CSBP after 12 weeks (<em>p</em> <!-->=<!--> <!-->&lt;0.001). The two treatment groups did not exert significant efficacy in lowering heart rate (HR) and augmentation index% (AIx%).</p></div><div><h3>Conclusion</h3><p>To conclude, the amlodipine 10<!--> <!-->mg/candesartan 16<!--> <!-->mg combination was non-inferior to the amlodipine 10<!--> <!-->mg/valsartan 160<!--> <!-->mg combination in terms of reducing peripheral and CBP over time.</p></div>\",\"PeriodicalId\":39403,\"journal\":{\"name\":\"Hipertension y Riesgo Vascular\",\"volume\":\"41 1\",\"pages\":\"Pages 17-25\"},\"PeriodicalIF\":1.2000,\"publicationDate\":\"2024-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Hipertension y Riesgo Vascular\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S1889183724000060\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"CARDIAC & CARDIOVASCULAR SYSTEMS\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Hipertension y Riesgo Vascular","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1889183724000060","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0

摘要

"氨氯地平/缬沙坦 "或 "氨氯地平/坎地沙坦 "组合是两种有效的降压药,其作用机制互补。然而,目前还没有研究评估氨氯地平/坎地沙坦对中心血压的影响,也没有将其与氨氯地平/缬沙坦复方制剂进行比较。与研究最多的 "氨氯地平加缬沙坦 "组合相比,"氨氯地平加坎地沙坦组合 "如何降低外周和中心血压?在一项开放标签的前瞻性研究中,86 名患者按 1:1 的比例随机分为两组。第一组(42 人)接受氨氯地平和缬沙坦组合治疗,第二组(44 人)接受氨氯地平和坎地沙坦组合治疗。在基线、随访 6 周和 12 周时测量外周血压和中心血压(CBP)。两个治疗组都降低了外周收缩压、舒张压和平均血压。两组之间和两组内部均无明显差异。治疗 12 周后,氨氯地平/坎地沙坦联合用药组的外周收缩压(PSBP)降幅更大(p= 0.5)。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Safety and efficacy of candesartan versus valsartan combined with amlodipine on peripheral and central blood pressure

Introduction

“Amlodipine/valsartan” or “amlodipine/candesartan” combinations represent two effective antihypertensive agents with complementary mechanisms of action. Nevertheless, a study has yet to be done to evaluate the effect of amlodipine/candesartan on central blood pressure and compare it with amlodipine/valsartan combination. To see how “amlodipine plus candesartan combination” reduces peripheral and central blood pressure compared to the most studied combination, “amlodipine plus valsartan”.

Material and methods

Eighty-six patients were randomized in an open-label, prospective study by 1:1 ratio to two groups. Group I (n = 42) received the amlodipine and valsartan combination, and group II (n = 44) received the amlodipine and candesartan combination. Peripheral and central blood pressure (CBP) was measured at baseline, at 6 and 12 weeks of follow-up.

Discussion

Both treatment groups reduced peripheral systolic, diastolic, and mean blood pressure. There was no significant difference between and within both groups. The amlodipine/candesartan combination showed more reduction in peripheral systolic blood pressure (PSBP) after 12 weeks of treatment (p = <0.001). Both groups decreased CBP without significant differences between groups. The amlodipine/candesartan combination showed additional efficacy in decreasing CSBP after 12 weeks (p = <0.001). The two treatment groups did not exert significant efficacy in lowering heart rate (HR) and augmentation index% (AIx%).

Conclusion

To conclude, the amlodipine 10 mg/candesartan 16 mg combination was non-inferior to the amlodipine 10 mg/valsartan 160 mg combination in terms of reducing peripheral and CBP over time.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Hipertension y Riesgo Vascular
Hipertension y Riesgo Vascular Medicine-Internal Medicine
CiteScore
1.70
自引率
16.70%
发文量
38
审稿时长
39 days
期刊介绍: La mejor publicación para mantenerse al día en los avances de la lucha contra esta patología. Incluye artículos de Investigación, Originales, Revisiones, Casos clínicos, Aplicación práctica y Resúmenes comentados a la bibliografía internacional. Además, es la Publicación Oficial de la Sociedad española de Hipertensión-Liga Española para la Lucha contra la Hipertensión Arterial.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信